# Mathematical Modeling Insights into Improving CAR T cell Therapy for Solid Tumors: Antigen Heterogeneity and Bystander Effects

Article · Erdi Kara, T. L. Jackson, Chartese Jones, Reginald L. McGee, Rockford Sison

- Archive id: arxiv:2307.05606
- Published: 2023-07-10
- Venue: npj Systems Biology and Applications, 10(1), 105 (2024)
- DOI: https://doi.org/10.1038/s41540-024-00435-4
- arXiv: https://arxiv.org/abs/2307.05606
- Citations: 18
- Source URL: https://arxiv.org/abs/2307.05606
- PDF: https://arxiv.org/pdf/2307.05606
- Provenance: arxiv

## Abstract

As an adoptive cellular therapy, Chimeric Antigen Receptor T-cell (CAR T-cell) therapy has shown remarkable success in hematological malignancies, but only limited efficacy against solid tumors. Compared with blood cancers, solid tumors present a unique set of challenges that ultimately neutralize the function of CAR T-cells. One such barrier is antigen heterogeneity - variability in the expression of the antigen on tumor cells. Success of CAR T-cell therapy in solid tumors is unlikely unless almost all the tumor cells express the specific antigen that CAR T-cells target. A critical question for solving the heterogeneity problem is whether CAR T therapy induces bystander effects, such as antigen spreading. Antigen spreading occurs when CAR T-cells activate other endogenous antitumor CD8 T cells against antigens that were not originally targeted. In this work, we develop a mathematical model of CAR T-cell therapy for solid tumors that takes into consideration both antigen heterogeneity and bystander effects. Our model is based on in vivo treatment data that includes a mixture of target antigen-positive and target antigen-negative tumor cells. We use our model to simulate large cohorts of virtual patients to gain a better understanding of the relationship between bystander killing. We also investigate several strategies for enhancing the bystander effect and thus increasing the overall efficacy of CAR T-cell therapy for solid tumor.

_Abstract reproduced under CC0-1.0 (arXiv descriptive metadata)._

Topics: [Gene & Cell Therapy](https://space-kitty.com/topics/gene-cell-therapy), [Cancer Immunotherapy](https://space-kitty.com/topics/cancer-immunotherapy)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.